Royalty Pharma plc (NASDAQ: RPRX) has announced that it will be releasing its financial results for the third quarter of 2024 on Wednesday 6th November 2024. The report will be made available before market open, allowing investors and analysts to evaluate the company's performance during this period.
According to the forecasts of financial experts on Wall Street, the business is expected to reveal an anticipated $0.93 profit per share for the quarter. Additionally, the firm is poised to disclose a quarterly revenue of $696.1 million.
Wall Street analysts have offered their forecasts for the company's yearly performance, predicting a total revenue of $2.65 billion. At the same time, they are expecting the company to achieve per share profit of $3.93 for the fiscal year ahead.
The company's earnings report for the corresponding quarter of the previous year showcased a per-share income of $0.79. This notable figure was achieved due to the company's impressive total revenue of $536 million recorded during that specific period.
| Period | EPS Actual |
EPS Growth* |
Revenue Actual |
Revenue Growth* |
|---|---|---|---|---|
| Historical Earnings Insight | ||||
| Q2 2024 | $0.96 | +14.3% | 537.00 M | -0.2% |
| Q1 2024 | $0.98 | -38.8% | 568.00 M | -17.0% |
| Q4 2023 | $1.15 | -26.3% | 596.00 M | +5.3% |
| Q3 2023 | $0.79 | +146.9% | 536.00 M | -6.5% |
| Q2 2023 | $0.84 | +20.0% | 538.00 M | +0.4% |
| *Growth on year-over-year basis | ||||
RPRX has scheduled a conference call on 6th November 2024 at 08:30 AM eastern time to discuss the third quarter financial results and other related information.
Friday's trading saw Royalty Pharma plc (RPRX) shares hit a low of $26.99 and a high of $27.27, with a day volume of 1.81 million shares. The stock closed the regular trading session at $27.10, showing 0.37 percent gain.
